menu
    • menu
    [{"orgOrder":0,"company":"Kamada","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Human Alpha 1 Proteinase Inhibitor","moa":"Alpha-1 antitrypsin protein","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Kamada","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.01,"dosageForm":"Inhaler","sponsorNew":"Kamada \/ Takeda","highestDevelopmentStatusID":"10","companyTruncated":"Kamada \/ Takeda"}]

    Find Clinical Drug Pipeline Developments & Deals for Human Alpha 1 Proteinase Inhibitor

    Menu

    Human Alpha 1 Proteinase Inhibitor

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kamada

                            Israel arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Kamada

                            Israel arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Alpha 1 Proteinase Inhibitor

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : $7.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Kamada Announces Amendment to GLASSIA® License Agreement with Takeda

                            Details : Following the completion of the transition of GLASSIA manufacturing, Kamada will transfer the product’s us biologics license application (BLA) to takeda.

                            Brand Name : Glassia

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 07, 2021

                            Lead Product(s) : Human Alpha 1 Proteinase Inhibitor

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : $7.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth